Brokerages expect Unum Therapeutics Inc (NASDAQ:UMRX) to post sales of $3.15 million for the current quarter, according to Zacks. Three analysts have issued estimates for Unum Therapeutics’ earnings. The lowest sales estimate is $1.80 million and the highest is $4.41 million. Unum Therapeutics posted sales of $2.22 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 41.9%. The company is scheduled to issue its next earnings report on Monday, May 13th.
According to Zacks, analysts expect that Unum Therapeutics will report full-year sales of $13.96 million for the current financial year, with estimates ranging from $7.00 million to $17.62 million. For the next fiscal year, analysts expect that the firm will post sales of $17.10 million, with estimates ranging from $9.00 million to $25.33 million. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that cover Unum Therapeutics.
Unum Therapeutics (NASDAQ:UMRX) last issued its quarterly earnings data on Thursday, March 28th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.33) by $0.04. The business had revenue of $3.80 million during the quarter, compared to the consensus estimate of $2.58 million. Unum Therapeutics had a negative return on equity of 96.46% and a negative net margin of 354.88%.
Shares of NASDAQ UMRX traded up $0.04 during midday trading on Thursday, hitting $3.60. 63,569 shares of the company’s stock were exchanged, compared to its average volume of 86,913. Unum Therapeutics has a twelve month low of $3.30 and a twelve month high of $17.66.
In related news, insider Seth Ettenberg sold 11,485 shares of the business’s stock in a transaction that occurred on Monday, March 25th. The stock was sold at an average price of $4.12, for a total transaction of $47,318.20. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Several hedge funds and other institutional investors have recently bought and sold shares of UMRX. American International Group Inc. increased its holdings in shares of Unum Therapeutics by 432.8% in the fourth quarter. American International Group Inc. now owns 12,531 shares of the company’s stock valued at $55,000 after buying an additional 10,179 shares in the last quarter. Jane Street Group LLC bought a new position in shares of Unum Therapeutics in the third quarter valued at $150,000. Bank of New York Mellon Corp increased its holdings in shares of Unum Therapeutics by 251.5% in the fourth quarter. Bank of New York Mellon Corp now owns 46,248 shares of the company’s stock valued at $204,000 after buying an additional 33,091 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in shares of Unum Therapeutics by 2,782.4% in the third quarter. JPMorgan Chase & Co. now owns 20,753 shares of the company’s stock valued at $213,000 after buying an additional 20,033 shares in the last quarter. Finally, Citadel Advisors LLC bought a new position in shares of Unum Therapeutics in the third quarter valued at $235,000. 47.46% of the stock is currently owned by institutional investors.
Unum Therapeutics Company Profile
Unum Therapeutics Inc, a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient's immune system to cure cancer. Its lead product candidate is the ACTR087 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory non-Hodgkin lymphoma.
Further Reading: Net Asset Value
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Unum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.